SINGAPORE, Dec. 08, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore-based leading non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced its plans to create an integrated digital health and rewards platform which will use a utility cryptocurrency called QB. The QB coins are being developed by a third party, and are scheduled to be launched sometime in January 2026 for use in EUDA’s digital health and wel ...

Core Viewpoint - EUDA Health Holdings Limited has entered into a securities purchase agreement with Streeterville Capital for a convertible warrant, aiming to strengthen its capital position and support growth strategies in the non-invasive healthcare market in Asia [1][4]. Company Overview - EUDA Health Holdings Limited is a Singapore-based non-invasive healthcare provider focusing on Singapore, Malaysia, and China, with a mission to lead the transformation of healthcare from reactive treatment to proactive, longevity-focused care [5]. - The company targets the fast-growing longevity sector, addressing the healthcare needs of over 1.8 billion people in the region, where more than 30% of the population is aging rapidly [5]. Financial Details - The securities purchase agreement involves the sale of a convertible warrant for an aggregate purchase price of US$100,000, which is exercisable for up to 2,000,000 newly issued ordinary shares at an exercise price of US$6.00 per share [1][3]. - The warrant can be exercised for cash within a 90-day period, with conditions allowing the company to require Streeterville Capital to exercise the warrant under specific trading volume and price conditions [3]. Strategic Intent - The CEO of EUDA emphasized that the warrant financing provides flexibility to invest in high-return initiatives, including new centers, partnerships, and technology, to expand the company's footprint in Asia's non-invasive healthcare market [4].

Core Viewpoint - EUDA Health Holdings Limited has secured exclusive worldwide distribution rights for a next-generation immune health supplement, enhancing its wellness product portfolio and positioning itself in the molecular precision wellness market [1][7]. Group 1: Company Overview - EUDA Health Holdings Limited is a leading non-invasive healthcare provider based in Singapore, focusing on markets in Singapore, Malaysia, and China [1][8]. - The company aims to become a market leader in non-invasive and preventive healthcare, targeting the fast-growing longevity sector to address the healthcare needs of over 1.8 billion people in the region [8][10]. Group 2: Product Details - The newly acquired supplement, branded as Euda Helixé, is designed to modulate gene expression, enhancing metabolism, boosting vitality, and supporting longevity through advanced epigenetic technology [2][3]. - The supplement combines premium-grade ingredients and utilizes a capsule delivery system that ensures active ingredients survive stomach acid for optimal absorption [4][9]. Group 3: Market Strategy - EUDA plans to initially market and sell the supplement in Singapore, Malaysia, and China, with future expansion into other markets [2]. - The company anticipates generating sales of approximately 500,000 bottles over the next 12 months, leveraging its strong regional ecosystem and distribution capabilities [7]. Group 4: Scientific Background - The supplement is developed by Chemokine Pte. Ltd., founded by Professor Kah Meng Lim, a respected molecular medicine researcher with a Ph.D. from the National University of Singapore [6]. - The formulation builds on prior scientific advancements and proven platforms to deliver molecular-level wellness support [4].